A research team showed that, contrary to current models, one early embryonic cell dominates lineages that will become the ...

Q1 2024 Earnings Call Transcript Lineage Cell Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at ...

LCTX stock results show that Lineage Cell Therapeutics met analyst estimates for earnings per share but beat on revenue for ...

Baird raised the price target for the Lineage Cell Therapeutics Inc (AMEX:LCTX) stock to “an Outperform”. The rating was released on November 02, 2022, according to finviz. The research report from ...

Cash Position: Ended Q1 2024 with $43.6 million in cash and equivalents, expected to support operations into Q3 2025. R&D Expenses: Reduced to $3.0 million in Q1 2024 from $4.2 million in Q1 2023, ...

CARLSBAD, Calif. (AP) — CARLSBAD, Calif. (AP) — Lineage Cell Therapeutics, Inc. (LCTX) on Thursday reported a loss of $6.5 million in its first quarter. On a per-share basis, the Carlsbad, ...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its first quarter ...

CARLSBAD, Calif. (AP) — CARLSBAD, Calif. (AP) — Lineage Cell Therapeutics, Inc. (LCTX) on Thursday reported a loss of $6.5 million in its first quarter. On a per-share basis, the Carlsbad ...